A61K 38/33
Derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
Official title: derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
A61K38/33 (Derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin) appears on 237 US grants and 375 published applications in this corpus.
Search patents in A61K- Granted patents
- 237
- Published applications
- 375
- Assignees
- 182
- Inventors
- 590
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 2 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 4 | 0 |
| 1990 | 2 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 6 | 0 |
| 1996 | 6 | 0 |
| 1997 | 4 | 0 |
| 1998 | 4 | 0 |
| 1999 | 7 | 0 |
| 2000 | 4 | 0 |
| 2001 | 1 | 2 |
| 2002 | 3 | 15 |
| 2003 | 4 | 15 |
| 2004 | 8 | 14 |
| 2005 | 6 | 16 |
| 2006 | 2 | 18 |
| 2007 | 4 | 12 |
| 2008 | 2 | 13 |
| 2009 | 2 | 16 |
| 2010 | 8 | 33 |
| 2011 | 3 | 14 |
| 2012 | 14 | 12 |
| 2013 | 15 | 18 |
| 2014 | 9 | 26 |
| 2015 | 4 | 18 |
| 2016 | 21 | 22 |
| 2017 | 16 | 19 |
| 2018 | 11 | 12 |
| 2019 | 11 | 17 |
| 2020 | 6 | 9 |
| 2021 | 5 | 17 |
| 2022 | 8 | 10 |
| 2023 | 5 | 8 |
| 2024 | 5 | 8 |
| 2025 | 6 | 5 |
| 2026 | 3 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Kits for preparing and delivering purified corticotropin15 Sep 2026US 12,734,217 B1ANI Pharmaceuticals, Inc.
- Methods of administering chimeric antigen receptor immunotherapy18 Aug 2026US 12,709,639 B2Kite Pharma, Inc.
- Method of diagnosis of adrenal insufficiency5 May 2026US 12,616,736 B2Sheffield Children's NHS Foundation Trust
- Kits for preparing and delivering purified corticotropin14 Oct 2025US 12,440,542 B1ANI Pharmaceuticals, Inc.
- Kits for preparing and delivering purified corticotropin10 Jun 2025US 12,324,787 B1ANI Pharmaceuticals, Inc.
- Murine stem cell factor polypeptides, compositions, and methods of use10 Sep 2026US 2026/0263610 A1Elixr Ltd
- MC4 Antagonists in the Treatment of Restless Legs Syndrome9 Jul 2026US 2026/0191926 A1
- Compositions for the treatment of disease4 Jun 2026US 2026/0151434 A1SightStream Biotherapeutics, Inc.
- Gene therapy vectors for the expression of preprodynorphin variants for the treatment of epilepsy21 May 2026US 2026/0137810 A1Charite-Universitatsmedizin Berlin
- Methods of stimulating appetite and/or increasing body weight using non-naturally occurring melanocortin receptor antagonist analogs9 Apr 2026US 2026/0098072 A1Endevica Bio, Inc.
Most cited
By later US patents
- Prolonged release microcapsule and its production372US 4,652,441 ATakeda Chemical Industries, Ltd. · 1987
- Modulated release from biocompatible polymers263US 5,656,297 AAlkermes Controlled Therapeutics, Inc. · 1997
- Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists245US 6,096,756 AAlbert Einstein College of Medicine of Yeshiva University · 2000
- Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists234US 5,472,943 AAlbert Einstein College of Medicine of Yeshiva University · 1995
- Prolonged release microcapsule of a water-soluble drug226US 5,061,492 ATakeda Chemical Industries, Ltd. · 1991